Clinical Trial

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label phase 2 study designed to explore the efficacy and safety of low-dose PTCy-ruxolitinib GVHD prophylaxis in older adults undergoing allogeneic HCT with a matched sibling or unrelated donor with a peripheral blood stem cell graft.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-11-11; most recent amendment 2026-03-10.
Status change: Suspended → Active, Not Recruiting 2026-03-10
Status change: Recruiting → Suspended 2025-10-17
Status change: Not Yet Recruiting → Recruiting 2023-08-29
Trial Details
NCT Number NCT05622318
Lead Sponsor Medical College of Wisconsin
Conditions Graft-versus-host Disease
Enrollment 56 participants
Start Date 2023-08-29
Primary Completion 2026-07 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-12